Optimization of Pyrrolamide Topoisomerase II Inhibitors Toward Identification of an Antibacterial Clinical Candidate (AZD5099)-Reference-Cited by-同舟云学术

Optimization of Pyrrolamide Topoisomerase II Inhibitors Toward Identification of an Antibacterial Clinical Candidate (AZD5099)

Published:2014-07-08 Issue:14 Volume:57 Page:6060-6082
ISSN:0022-2623
Container-title:Journal of Medicinal Chemistry
language:en
Short-container-title:J. Med. Chem.

Author:

Basarab Gregory S.¹,Hill Pamela J.¹,Garner C. Edwin¹,Hull Ken¹,Green Oluyinka¹,Sherer Brian A.¹,Dangel P. Brian¹,Manchester John I.¹,Bist Shanta¹,Hauck Sheila¹,Zhou Fei¹,Uria-Nickelsen Maria¹,Illingworth Ruth¹,Alm Richard¹,Rooney Mike¹,Eakin Ann E.¹

Affiliation:

1. Infection Innovative Medicines, AstraZeneca R&D Boston, 35 Gatehouse Drive, Waltham, Massachusetts 02451, United States

Publisher

American Chemical Society (ACS)

Subject

Drug Discovery,Molecular Medicine

Link

https://pubs.acs.org/doi/pdf/10.1021/jm500462x

Reference67 articles.

1. Pyrrolamide DNA Gyrase Inhibitors: Fragment-Based Nuclear Magnetic Resonance Screening To Identify Antibacterial Agents

2. Pyrrolamide DNA gyrase inhibitors: Optimization of antibacterial activity and efficacy

3. Progress and Challenges in Implementing the Research on ESKAPE Pathogens